Pharmaceutical
Medical Devices
Technology

Daiichi Sankyo

$49.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.48 (-2.90%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Daiichi Sankyo and other stocks, options, ETFs, and crypto commission-free!

About

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. Read More The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. DSNKY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
14,446
Headquarters
Tokyo, Tokyo
Founded
2005
Market Cap
32.97B
Price-Earnings Ratio
38.08
Dividend Yield
1.60
Average Volume
15.95K
High Today
$50.89
Low Today
$49.33
Open Price
$50.89
Volume
5.97K
52 Week High
$53.06
52 Week Low
$30.00

Collections

Pharmaceutical
Medical Devices
Technology
Health
Medical
Asia (Non-China)
Asia

News

ReutersMay 14

FDA advisory panel votes against Daiichi Sankyo's cancer treatment

(Reuters) - Independent experts on an FDA advisory panel on Tuesday voted against Daiichi Sankyo Co Ltd’s treatment for adults with a type of acute myeloid leukemia.

22
Seeking AlphaMay 13

Daiichi Sankyo launches MINNEBRO tablets in Japan

Exelixis' (NASDAQ:EXEL) partner Daiichi Sankyo (OTCPK:DSNKY) has launched MINNEBRO (esaxerenone) tablets as a treatment for patients with hypertension in Japan.

94
Yahoo FinanceMay 13

Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® (Esaxerenone) Tablets in Japan

ALAMEDA, Calif.--(BUSINESS WIRE)-- -- First commercial sale triggers $20 million milestone payment to Exelixis -- Exelixis, Inc. (EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO® (esaxerenone) tablets as a treatment for patients with hypertension in Japan. With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies’ collaboration agr...

37
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.